A Iowa overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
36.6% of Iowa adults have obesity, per the CDC's 2024 BRFSS statewide direct-survey estimate (95% CI 35.3–38.0, n=8,067) — up from 29.0% in 2011, and above the 2024 cross-state median of 33.1% 4. This is a statewide figure; Davenport and Des Moines carry CDC PLACES place-level modeled estimates on their own pages, a different methodology and geography that should not be summed or plotted against this one.
Iowa's population was 3,241,488 as of the Census Vintage 2024 estimates 5. Iowa reads as a flat no on paper, but the useful answer is exactly where the line sits.
Iowa Medicaid's fee-for-service program categorically excludes "drugs used for anorexia, weight gain, or weight loss" (441 Iowa Admin. Code r. 78.2(4)"b"(2), current, eff. 7/1/2026) 1.
But Iowa's own Preferred Drug List (eff. 7/1/2026) keeps Wegovy and Zepbound "Preferred," payable only through prior authorization (PA Form 470-0058, rev. 1/26) for three non-diabetes indications: (1) reducing cardiovascular risk in a patient with established heart disease and obesity/overweight (BMI >= 27), (2) moderate-to-severe obstructive sleep apnea (Zepbound only), or (3) noncirrhotic MASH (Wegovy only) 23. Obesity or weight loss as the primary, standalone diagnosis is not payable under any of these pathways.
This is Iowa Medicaid's fee-for-service program specifically. Most Iowa Medicaid enrollees are in IA Health Link managed care (Iowa Total Care, Molina Healthcare of Iowa), and those plans' alignment with this PDL was not independently confirmed for this page.
Our price in Iowa is the same as our price everywhere else — $68/month for semaglutide, $118/month for tirzepatide, both on a 12-month plan ($816 / $1,416 billed annually).
Median household income in Iowa is $75,501 (ACS 2024 1-year, Table B19013) 6. We publish one national number rather than pricing against a local market.
TODO — Iowa's specific telehealth-prescribing and compounding rule has not been verified for this page. Pharmacy practice in the state is overseen by the Iowa Board of Pharmacy, reachable through Iowa DIAL (the older plb.iowa.gov and pharmacy.iowa.gov addresses both redirect there) 7. No Iowa-specific rule is asserted here beyond the general federal framework until that verification is done.
Astra is licensed to treat patients in Iowa and in all 50 states.
Astra treats patients in Iowa through state-licensed physicians.
Davenport and Des Moines city pages carry local cost and coverage detail.
Only in a narrow sense. Iowa Medicaid's fee-for-service program categorically excludes weight-loss drugs by rule, but its own Preferred Drug List keeps both Wegovy and Zepbound "Preferred" for three specific non-diabetes conditions — cardiovascular risk reduction with obesity, moderate-to-severe sleep apnea (Zepbound), or noncirrhotic MASH (Wegovy) — each requiring prior authorization. Obesity or weight loss alone is never a payable reason.
No. Astra's price does not change by state: $68/month for semaglutide and $118/month for tirzepatide, both on a 12-month plan ($816 / $1,416 billed annually) — the same in Iowa as everywhere else Astra serves.
Iowa's administrative code (441-78.2(4)"b"(2)) categorically excludes "drugs used for anorexia, weight gain, or weight loss" from Medicaid pharmacy coverage. That's a state policy choice, not an FDA or manufacturer restriction — the same drugs stay payable through Iowa Medicaid's fee-for-service program for the specific non-diabetes indications above, and for diabetes.
[TODO — Iowa's specific telehealth-prescribing / compounding rule has not been verified for this page yet. Do not publish a state-specific legal claim beyond the general federal framework until this is confirmed. See the Iowa Board of Pharmacy: https://dial.iowa.gov/licenses/health-professions/pharmacy]
Yes. Astra is licensed in all 50 states, including Iowa. See the Davenport and Des Moines pages for city-specific cost and coverage detail.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.